Log in

Relevant bibliographies by topics / Antisecretory drug / Journal articles

To see the other types of publications on this topic, follow the link: Antisecretory drug.

Journal articles on the topic 'Antisecretory drug'

Author: Grafiati

Published: 5 June 2025

Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antisecretory drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

HANSTEN, P. D. "Drug interactions with antisecretory agents." Alimentary Pharmacology & Therapeutics 5 (March 31, 2007): 121–28. http://dx.doi.org/10.1111/j.1365-2036.1991.tb00755.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zwisler, Jon Eik, Dorte Ejg Jarbøl, Annmarie Touborg Lassen, Jakob Kragstrup, Niels Thorsgaard, and Ove B. Schaffalitzky de Muckadell. "Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice." International Journal of Family Medicine 2015 (July 12, 2015): 1–7. http://dx.doi.org/10.1155/2015/175436.

Full text

Abstract:

Objective. To investigate whether patients on long-term antisecretory medication need to continue treatment to control symptoms. Methods. A double-blinded randomised placebo-controlled trial in general practices in Denmark. Patients aged 18–90 who were treated with antisecretory drugs on a long-term basis were randomized to esomeprazole 40 mg or identical placebo. Outcome measures were time to discontinuation with trial medication due to failed symptom control analysed as survival data. The proportion of patients stopping trial medication during the one-year follow-up was estimated. Results. A

APA, Harvard, Vancouver, ISO, and other styles

3

Lopina, O. D., B. K. Nurgalieva, and T. L. Lapina. "Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole." Russian Journal of Gastroenterology, Hepatology, Coloproctology 31, no. 4 (2021): 55–63. http://dx.doi.org/10.22416/1382-4376-2021-31-4-55-63.

Full text

Abstract:

Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. A faster antisecretory effect and higher acid-suppressive activity of rabeprazole determine its better clinical efficacy in treatmen

APA, Harvard, Vancouver, ISO, and other styles

4

Lazzaroni, M., O. Sangaletti, and G. Bianchi Porro. "The Effect of a Single Oral Morning Dose of Nizatidine and Ranitidine on Intragastric pH under Basal Conditions and after Pentagastrin Stimulation." Journal of International Medical Research 20, no. 6 (1992): 454–60. http://dx.doi.org/10.1177/030006059202000602.

Full text

Abstract:

A comparison was made of the antisecretory activity of orally administered nizatidine and ranitidine by measuring intragastric pH under basal conditions and during and after pentagastrin stimulation. Intragastric pH values were measured with a bipolar glass electrode in 10 patients with healed duodenal ulcers treated with nizatidine or ranitidine according to a randomized single-blind design. The antisecretory activity of the two drugs was similar during the 4 h of monitoring following drug administration. Nizatidine, however, showed a more rapid inhibitory action than ranitidine, producing a

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Drug interactions with antisecretory agents are examined." Reactions Weekly &NA;, no. 369 (1991): 3–4. http://dx.doi.org/10.2165/00128415-199103690-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Krivopalov, A. A., S. V. Ryazansev, and P. A. Shamkina. "Complex homeopathic therapy of acute infectious rhinitis." Meditsinskiy sovet = Medical Council, no. 8 (April 18, 2019): 38–42. http://dx.doi.org/10.21518/2079-701x-2019-8-38-42.

Full text

Abstract:

The article is devoted to the use of the combined drug Coryzalia in the treatment of acute rhinitis. The advantages of Coryzalia are the possibility of using it at any stage of treatment, combination with other drugs. The complex of active ingredients that make up the drug, has anti-inflammatory, antisecretory and detoxifying effects. The results of various studies confirm the high safety profile and efficacy of Coryzalia not only for adults, but also for treatment of children.

APA, Harvard, Vancouver, ISO, and other styles

7

Locci, Cristian, Laura Cuzzolin, Gianluca Cheri, Laura Saderi, Giovanni Sotgiu, and Roberto Antonucci. "Clinical Use of Gastric Antisecretory Drugs in Hospitalized Pediatric Patients." Journal of Clinical Medicine 12, no. 1 (2023): 368. http://dx.doi.org/10.3390/jcm12010368.

Full text

Abstract:

Antisecretory drugs are frequently used in the treatment of pediatric gastrointestinal disorders. This study was aimed to assess the prescribing patterns and the safety of ranitidine and proton pump inhibitors (PPIs) in a cohort of Italian pediatric patients. Children aged >1 month to <16 years that were admitted to our Pediatric Clinic between 2016 and 2018 were enrolled in this retrospective observational study. All data were obtained from medical records and a parent telephone questionnaire. The exclusion criteria included the use of antisecretory therapy at hospital admission, failur

APA, Harvard, Vancouver, ISO, and other styles

8

Chernikov, M. V., M. A. Oganova, A. S. Gerasimenko, and E. A. Artemyev. "STUDY OF ANTISECRETORY ACTIVITY OF DINITRATE 2-PHENYL-9-DIETHYLAMINOETHYLimidazo[1,2-A] BENZIMIDAZOLE BY METHOD OF CONTINUOUS PERFUSION OF RATS’ STOMACHS." Pharmacy & Pharmacology 7, no. 4 (2019): 231–40. http://dx.doi.org/10.19163/2307-9266-2019-7-4-231-240.

Full text

Abstract:

Nowadays, effective pharmacotherapy of acid-dependent gastrointestinal diseases remains an urgent problem of modern gastroenterology. In this regard, the search for new drugs with a pronounced antisecretory activity still continues; their aim is to keep the control over the acid production safe and effective.The aim of this study was an experimental study of the antisecretory activity of the substance and the finished dosage form (FDF) of dinitrate 2-phenyl-9-diethylaminoethylimidazo[1,2-a]benzimidazole.Materials and Methods. The study of antisecretory activity was performed by method of a con

APA, Harvard, Vancouver, ISO, and other styles

9

Saeed, Zahid A., Jeffrey A. Norton, William O. Frank, et al. "Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome." Gastroenterology 96, no. 6 (1989): 1393–402. http://dx.doi.org/10.1016/0016-5085(89)90504-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Jones, James B., and Robert T. Bailey. "Misoprostol: A Prostaglandin E, Analog with Antisecretory and Cytoprotective Properties." DICP 23, no. 4 (1989): 276–82. http://dx.doi.org/10.1177/106002808902300401.

Full text

Abstract:

Misoprostol, a methylester analog of prostaglandin E1, with antisecretory and cytoprotective properties, has undergone extensive investigation and has received Food and Drug Administration approval for the prevention of nonsteroidal-induced ulceration. The drug represents the first synthetic, orally active prostaglandin evaluated for the treatment of peptic ulcer disease. Clinical studies reveal a trend toward slightly lower healing rates with misoprostol when compared with histamine (H2)-receptor antagonists in the treatment of gastric and duodenal ulcers. In addition, misoprostol was less ef

APA, Harvard, Vancouver, ISO, and other styles

11

Padol, Ireneusz T., and Richard H. Hunt. "Host-specific differences in the physiology of acid secretion related to prostaglandins may play a role in gastric inflammation and injury." American Journal of Physiology-Gastrointestinal and Liver Physiology 288, no. 6 (2005): G1110—G1117. http://dx.doi.org/10.1152/ajpgi.00364.2004.

Full text

Abstract:

Immune mediators are involved in strain-specific manifestations of Helicobacter pylori infection, and the type of immune response is associated with production of PGE2, which in turn influences gastric acid secretion. Acid secretion plays a pivotal role, not only in the pattern of H. pylori-induced gastritis and its consequences, but also in nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathies. Mice and their transgenic modifications are widely used in Helicobacter and eicosanoid research. Using [14C]aminopyrine accumulation and pylorus ligation, we aimed to study acid secretion i

APA, Harvard, Vancouver, ISO, and other styles

12

de Hostos, Eugenio L., Robert KM Choy, and Tue Nguyen. "Developing novel antisecretory drugs to treat infectious diarrhea." Future Medicinal Chemistry 3, no. 10 (2011): 1317–25. http://dx.doi.org/10.4155/fmc.11.87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Herszényi, Lászlo, Tamás Bakucz, Loránd Barabás, and Zsolt Tulassay. "Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future." Digestive Diseases 38, Suppl. 2 (2019): 104–11. http://dx.doi.org/10.1159/000505204.

Full text

Abstract:

Less than 2 centuries have elapsed since the identification of hydrochloric acid in the stomach. The clarification of the molecular mechanisms allowed the effective therapeutic suppression of gastric acid secretion. The spectacular advances in the treatment of acid-related disorders represent a synthesis of the contributions of several brilliant pharmacologists, basic scientists, and clinical physicians. Effective gastric acid suppressive therapy has dramatically improved the therapy and outcome of acid-related disorders. The introduction of proton pump inhibitors (PPIs) in clinical practice h

APA, Harvard, Vancouver, ISO, and other styles

14

Levy, Steven, Mona M. Abaza, Mary J. Hawkshaw, and Robert T. Sataloff. "Psychiatric Manifestations of Medications Commonly Prescribed in Otolaryngology." Ear, Nose & Throat Journal 80, no. 4 (2001): 266–71. http://dx.doi.org/10.1177/014556130108000416.

Full text

Abstract:

Otolaryngologists, nurses, and psychological professionals should be familiar with the potential psychiatric side effects of medications that are commonly prescribed by otolaryngologists. Because some of these side effects are atypical, their relationship to medications might not be obvious. An awareness of the potential for psychiatric side effects caused by adrenocorticoids, antihistamines and decongestants, and antisecretory medications will help the clinician avoid or detect and treat drug-induced disorders, as will an awareness of the potential for side effects caused by combinations of m

APA, Harvard, Vancouver, ISO, and other styles

15

Meddah, Bouchra, Nicolas Limas-Nzouzi, Godefroy Mamadou, Joe Miantezila, Imar Djibrine Soudy, and Bruno Eto. "Antisecretory effect of prescribed appetite stimulator drug cyproheptadine in rat intestine." Fundamental & Clinical Pharmacology 28, no. 3 (2013): 303–9. http://dx.doi.org/10.1111/fcp.12029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

BERZSENYI, P., L. SEBESTYEN, M. MARTONMERESZ, and F. ANDRASI. "GYKI 34 655: A potent gastric antisecretory and antiulcer/cytoprotective drug." Pharmacological Research 31 (1995): 94. http://dx.doi.org/10.1016/1043-6618(95)86636-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Berzsenyi, P., F. Andrási, G. Zólyomi, E. Ezer, and M. Nakamura. "GYKI 60 043: A potent gastric antisecretory and antiulcer/cytoprotective drug." European Journal of Pharmacology 183, no. 2 (1990): 295–96. http://dx.doi.org/10.1016/0014-2999(90)93150-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ito, Tetsuhide, Irene Ramos-Alvarez, and Robert T. Jensen. "Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES." Cancers 15, no. 5 (2023): 1377. http://dx.doi.org/10.3390/cancers15051377.

Full text

Abstract:

Analysis of the efficacy/pharmacology of long-term/lifetime medical treatment of acid hypersecretion in a large cohort of ZES patients in a prospective study. This study includes the results from all 303 patients with established ZES who were prospectively followed and received acid antisecretory treatment with either H2Rs or PPIs, with antisecretory doses individually titrated by the results of regular gastric acid testing. The study includes patients treated for short-term periods (<5 yrs), patients treated long-term (>5 yrs), and patients with lifetime treatment (30%) followed for up

APA, Harvard, Vancouver, ISO, and other styles

19

Lindberg, Per, Peter Nordberg, Tomas Alminger, Arne Braendstroem, and Bjoern Wallmark. "The mechanism of action of the antisecretory agent omeprazole." Journal of Medicinal Chemistry 29, no. 8 (1986): 1327–29. http://dx.doi.org/10.1021/jm00158a001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

MATTOS, Ângelo Zambam de, Gabriela Meirelles MARCHESE, Bárbara Brum FONSECA, Carlos KUPSKI, and Marta Brenner MACHADO. "ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW." Arquivos de Gastroenterologia 54, no. 4 (2017): 271–80. http://dx.doi.org/10.1590/s0004-2803.201700000-42.

Full text

Abstract:

ABSTRACT BACKGROUND: Proton pump inhibitors and histamine H2 receptor antagonists are two of the most commonly prescribed drug classes for pediatric gastroesophageal reflux disease, but their efficacy is controversial. Many patients are treated with these drugs for atypical manifestations attributed to gastroesophageal reflux, even that causal relation is not proven. OBJECTIVE: To evaluate the use of proton pump inhibitors and histamine H2 receptor antagonists in pediatric gastroesophageal reflux disease through a systematic review. METHODS: A systematic review was performed, using MEDLINE, EM

APA, Harvard, Vancouver, ISO, and other styles

21

Mustacchi, Giorgio, and Rita Ceccherini. "La Gastroprotezione Nel Paziente Oncologico: Approccio Razionale, Ruolo Dei Farmaci Antisecretori Ed Eventuali Ulteriori Prospettive in Oncologia." Tumori Journal 84, no. 1_suppl1 (1998): S16—S19. http://dx.doi.org/10.1177/03008916980841s104.

Full text

Abstract:

In view of the large number of cancer patients treated with FANS and/or corticosteroids for long periods of time, Authors discuss how the use of antisecretory drugs for gastroprotection has become common practice in spite of the lack of clear scientific evidence. The paper analyses the principal mechanisms of gastrotoxicity of FANS, essentially associated with the inhibition of prostaglandins and consequent reduction of the secretion of mucous and bicarbonate. It also discusses the numerous controlled trials evaluating the efficacy of ranitidine for gastroprotection versus placebo and versus t

APA, Harvard, Vancouver, ISO, and other styles

22

Caner, Hava, James R. Cheeseman, and Israel Agranat. "Conformational spaces of the gastrointestinal antisecretory chiral drug omeprazole: Stereochemistry and tautomerism." Chirality 18, no. 1 (2005): 10–16. http://dx.doi.org/10.1002/chir.20214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Dombrower, Paul M. "Pantoprazole: A New Proton-Pump Inhibitor." Journal of Pharmacy Practice 12, no. 6 (1999): 504–10. http://dx.doi.org/10.1177/089719009901200608.

Full text

Abstract:

Pantoprazole, a new substituted benzimidazole, is reviewed for its use in the treatment of gastroesophageal reflux disease (GERD). In the intravenous form, pantoprazole has a rapid onset of antisecretory effect. The oral formulation has good oral bioavailability and chemical stability in mild to moderate acid conditions. Other positive attributes include lack of significant adverse effects and drug interactions, minimal effect of renal and hepatic impairment on drug disposition, and its ability to control gastric pH > 4.0. In comparative studies, it has been shown to be more effective than

APA, Harvard, Vancouver, ISO, and other styles

24

Scott, Malcolm K., Henry I. Jacoby, Antoinette C. Bonfilio, Thomas W. Corcoran, and Iris S. Lopez. "Antisecretory activity of human, dog, and rat metabolites of fenoctimine." Journal of Medicinal Chemistry 30, no. 5 (1987): 894–99. http://dx.doi.org/10.1021/jm00388a025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Pitzele, Barnett S., Alan E. Moormann, Gary W. Gullikson, et al. "Potential antisecretory antidiarrheals. 1. .alpha.2-Adrenergic aromatic aminoguanidine hydrazones." Journal of Medicinal Chemistry 31, no. 1 (1988): 138–44. http://dx.doi.org/10.1021/jm00396a020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Velázquez, Claudia, Fernando Calzada, Javier Torres, Felipe González, and Guillermo Ceballos. "Antisecretory activity of plants used to treat gastrointestinal disorders in Mexico." Journal of Ethnopharmacology 103, no. 1 (2006): 66–70. http://dx.doi.org/10.1016/j.jep.2005.06.046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Shine, V. J., S. Shyamal, P. G. Latha, and S. Rajasekharan. "Gastric Antisecretory and Antiulcer Activities ofDecalepis arayalpathra." Pharmaceutical Biology 45, no. 3 (2007): 210–16. http://dx.doi.org/10.1080/13880200701213138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Khan, Arif-ullah, and Anwarul Hassan Gilani. "Antidiarrheal, antisecretory, and bronchodilatory activities ofHypericum perforatum." Pharmaceutical Biology 47, no. 10 (2009): 962–67. http://dx.doi.org/10.1080/13880200902960206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Suvakovic, Z., M. G. Bramble, R. Jones, C. Wilson, N. Idle, and J. Ryott. "Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study." Gut 41, no. 3 (1997): 308–13. http://dx.doi.org/10.1136/gut.41.3.308.

Full text

Abstract:

Background/aims—To explore the reasons why patients with gastric cancer continue to present with advanced disease despite open access gastroscopy.Patients—All patients diagnosed with gastric cancer between 1 August 1989 and 31 July 1994.Methods—A retrospective study of the presentation of gastric cancer in South Tees; patients were diagnosed at open access gastroscopy or referred through conventional channels. Primary care records of 81 patients dying between 1991 and 1995 were analysed for previous symptoms, investigations, and antisecretory drug therapy. Findings were compared with 200 age a

APA, Harvard, Vancouver, ISO, and other styles

30

Tytgat, G. N. J., O. J. Anker Hansen, L. Carling, et al. "Effect of Cisapride on Relapse of Reflux Oesophagitis, Healed with an Antisecretory Drug." Scandinavian Journal of Gastroenterology 27, no. 3 (1992): 175–83. http://dx.doi.org/10.3109/00365529208999945.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

LAHNER, E., B. ANNIBALE, and G. DELLE FAVE. "Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy." Alimentary Pharmacology & Therapeutics 29, no. 12 (2009): 1219–29. http://dx.doi.org/10.1111/j.1365-2036.2009.03993.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bonfils, Serge. "Nizatidine versus ranitidine: Evolution of drug antisecretory efficacy over a 28-day period." Current Therapeutic Research 52, no. 6 (1992): 859–62. http://dx.doi.org/10.1016/s0011-393x(05)80058-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

DiJoseph, John F., George J. Palumbo, Roger Crossley, Arthur A. Santilli, and Susan T. Nielsen. "Gastric antisecretory activity of an acid stable H+/K+ ATPase inhibitor, WY-26,769." Drug Development Research 23, no. 1 (1991): 57–64. http://dx.doi.org/10.1002/ddr.430230106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Moormann, Alan E., Barnett S. Pitzele, P. H. Jones, et al. "Potential antisecretory antidiarrheals. 2. .alpha.2-Adrenergic 2-[(aryloxy)alkyl]imidazolines." Journal of Medicinal Chemistry 33, no. 2 (1990): 614–26. http://dx.doi.org/10.1021/jm00164a024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Dajani, Esam Z., and Naurang M. Agrawal. "Prevention of IMonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Ulcers: Role of Mucosal Protective and Gastric Antisecretory Drugs." Digestive Diseases 13, no. 1 (1995): 48–61. http://dx.doi.org/10.1159/000171526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Adebayo, Muritala Ayofe, Oluwasegun Adekanmi Adedokun, Lateef Abiola Akinpelu, and Paul Okwudili Okafor. "Evaluation of Anti-Diarrheal Activity of Methanol Root Bark Extract of Milicia Excelsa (Welw) C. C Berg (Moraceae) in Rats." Drug Research 69, no. 08 (2019): 439–44. http://dx.doi.org/10.1055/a-0825-6337.

Full text

Abstract:

Abstract Milicia excelsa (Moraceae) plant is used as an antidiarrheal agent in ethnomedicine but there is no scientific rationale for its claim. Hence, this study examined the acute toxicity (LD50) and anti-diarrheal effect of methanol root bark extract of Milicia excelsa per oral in rats as well as the probable phytoconstituents responsible for this effect. The LD50 was>5000 mg/kg, suggesting its safety. The extract significantly (p<0.05) reduced the total number of feces and wet feces in castor oil-induced diarrhea with percentage inhibitions of 41.36 and 50.88% at 200 and 400 mg/kg re

APA, Harvard, Vancouver, ISO, and other styles

37

Backes, Charline Fernanda, Edyane Lopes, Airton Tetelbom, and Isabela Heineck. "Medication and nutritional supplement use before and after bariatric surgery." Sao Paulo Medical Journal 134, no. 6 (2016): 491–500. http://dx.doi.org/10.1590/1516-3180.2015.0241030516.

Full text

Abstract:

ABSTRACT CONTEXT AND OBJECTIVE: Bariatric surgery has been an effective alternative treatment for morbid obesity and has resulted in decreased mortality, better control over comorbidities and reduced use of drugs. The objective of this study was to analyze the impact of bariatric surgery on medication drug and nutritional supplement use. DESIGN AND SETTING: Longitudinal study of before-and-after type, on 69 morbidly obese patients in a public hospital in Porto Alegre. METHODS: Through interviews, the presence of comorbidities and use of drugs with and without prescription were evaluated. RESUL

APA, Harvard, Vancouver, ISO, and other styles

38

Jin, Byung-Ju, Jay R. Thiagarajah, and A. S. Verkman. "Convective washout reduces the antidiarrheal efficacy of enterocyte surface–targeted antisecretory drugs." Journal of General Physiology 141, no. 2 (2013): 261–72. http://dx.doi.org/10.1085/jgp.201210885.

Full text

Abstract:

Secretory diarrheas such as cholera are a major cause of morbidity and mortality in developing countries. We previously introduced the concept of antisecretory therapy for diarrhea using chloride channel inhibitors targeting the cystic fibrosis transmembrane conductance regulator channel pore on the extracellular surface of enterocytes. However, a concern with this strategy is that rapid fluid secretion could cause convective drug washout that would limit the efficacy of extracellularly targeted inhibitors. Here, we developed a convection–diffusion model of washout in an anatomically accurate

APA, Harvard, Vancouver, ISO, and other styles

39

Collins, Paul W., Alan F. Gasiecki, Peter H. Jones, et al. "Synthesis and gastric antisecretory properties of .alpha.-chain diene derivatives of misoprostol." Journal of Medicinal Chemistry 29, no. 7 (1986): 1195–201. http://dx.doi.org/10.1021/jm00157a013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Kumar, Avadhesh, Vandana Singh, and Amrendra Kumar Chaudhary. "Gastric antisecretory and antiulcer activities of Cedrus deodara (Roxb.) Loud. in Wistar rats." Journal of Ethnopharmacology 134, no. 2 (2011): 294–97. http://dx.doi.org/10.1016/j.jep.2010.12.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Melanchauski, Larissa S., Ana Paula G. S. Broto, Thiago M. Moraes, et al. "Gastroprotective and antisecretory effects of Ailanthus excelsa (Roxb)." Journal of Natural Medicines 64, no. 1 (2009): 109–13. http://dx.doi.org/10.1007/s11418-009-0373-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lichtenberger, LM, C. Ulloa, JJ Romero, AL Vanous, PA Illich, and EJ Dial. "Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: Combination therapy with antisecretory agents in rats." Gastroenterology 111, no. 4 (1996): 990–95. http://dx.doi.org/10.1016/s0016-5085(96)70066-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Smolyar, N. N., Yu M. Yutilov, and M. G. Abramyants. "Synthesis of 5-(n-isopropylthiocarbamoyl)-spinaceamines: Analogs of antisecretory and antiulcer derivatives of spinaceamine." Pharmaceutical Chemistry Journal 40, no. 2 (2006): 63–67. http://dx.doi.org/10.1007/s11094-006-0059-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Santilli, Arthur A., Anthony C. Scotese, Raymond F. Bauer, and Stanley C. Bell. "2-Oxo-1,8-naphthyridine-3-carboxylic acid derivatives with potent gastric antisecretory properties." Journal of Medicinal Chemistry 30, no. 12 (1987): 2270–77. http://dx.doi.org/10.1021/jm00395a015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Bulgakov, S. A. "Hexapeptide dalargin in clinical gastroenterology: 30 years' of clinical application of the drug." Russian Journal of Gastroenterology, Hepatology, Coloproctology 26, no. 3 (2016): 103–12. http://dx.doi.org/10.22416/1382-4376-2016-26-3-103-112.

Full text

Abstract:

Aim of review. To discuss results of application of the Russian drug dalargin in the treatment of gastroenterological diseases. Summary. Dalargin is the first synthetic opioid peptide agent created on the basis of endogenous leucineenkephaline. Pharmacological effects of dalargin are caused by opioid receptors. The pilot studies showed protective properties for ulceration and antisecretory effect. In therapeutic practice it is applied for treatment of peptic ulcer of the stomach and duodenum, acute and chronic pancreatitis and pancreatic necrosis. Article presents results of use of hexapeptide

APA, Harvard, Vancouver, ISO, and other styles

46

Kuligin, A. V., K. A. Ershova, A. K. Borisov, M. S. Yakovenko, A. V. Borota, and N. K. Ibragimov. "Evaluation of the effectiveness of pharmacotherapy in intensive care patients with erosive and ulcerative lesions of the gastroduodenal zone of mixed genesis complicated by bleeding." Messenger of ANESTHESIOLOGY AND RESUSCITATION 22, no. 3 (2025): 129–35. https://doi.org/10.24884/2078-5658-2025-22-3-129-135.

Full text

Abstract:

The objective was to evaluate the effectiveness of antisecretory therapy in patients in critical surgical condition with complicated erosive and ulcerative lesions of the gastric mucosa and/or duodenum of mixed origin complicated by bleeding. Materials and methods. The observational study included 30 patients who were hospitalized between March and December 2024. The patients were divided into two groups. The control group included 15 patients receiving Omeprazole gastroprotective therapy, and the comparison group included 15 patients receiving Lanson-AF therapy. The results of the study were

APA, Harvard, Vancouver, ISO, and other styles

47

Perkins, William E., Paul W. Collins, Robert G. Bianchi, et al. "Antisecretory, mucosal-protective, and diarrheagenic activity of a novel synthetic prostaglandin, SC-46275, in the rat." Drug Development Research 23, no. 4 (1991): 349–58. http://dx.doi.org/10.1002/ddr.430230408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Butov, M. A., M. Msakni, and V. M. Butova. "The effect of rabeprazole on the secretory and motor function of the gastrointestinal tract." Experimental and Clinical Gastroenterology, no. 11 (March 26, 2024): 67–74. http://dx.doi.org/10.31146/1682-8658-ecg-219-11-67-74.

Full text

Abstract:

Parietal cell proton pump inhibitors (PPIs) have become firmly established in clinician practice. When discussing the features of their action, as a rule, researchers focus on their antisecretory effect. In the available literature, we found only a single report on the effect of PPIs on the motor-evacuation function of the gastrointestinal tract (GIT). We have found that the PPI rabeprazole not only has an antisecretory effect, but also normalizes the motor-evacuation function of all parts of the gastrointestinal tract. In this regard, it can be used in patients with gastric hypersecretion in

APA, Harvard, Vancouver, ISO, and other styles

49

Hyman, P. E., T. Q. Garvey, and T. Harada. "Effect of Ranitidine on Gastric Acid Hypersecretion in an Infant with Short Bowel Syndrome." Journal of Pediatric Gastroenterology and Nutrition 4, no. 2 (1985): 316–19. http://dx.doi.org/10.1002/j.1536-4801.1985.tb08844.x.

Full text

Abstract:

We studied the effect of ranitidine given in graded bolus intravenous doses on gastric acid hypersecretion in an unfed 3‐month‐old male with short bowel syndrome. We measured gastric volume and H+ serially for 12 h following each bolus and correlated inhibition of H+ secretion with plasma ranitidine concentration. In the first 4 h post drug, doses of 0.3, 1.0, 2.0, and 4.0 mg/kg resulted in 78, 93, 97, and 98% inhibition, respectively. The cumulative 12‐h effect of the drug was to inhibit H+ secretion 67, 63, 72, and 87%. The IC50 for H+ secretion was between 50 and 100 ng/ml, and the IC90 bet

APA, Harvard, Vancouver, ISO, and other styles

50

Shine, V. J., P. G. Latha, S. Shyamal, et al. "Gastric antisecretory and antiulcer activities of Cyclea peltata (Lam.) Hook. f. & Thoms. in rats." Journal of Ethnopharmacology 125, no. 2 (2009): 350–55. http://dx.doi.org/10.1016/j.jep.2009.04.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!